甲状腺癌早期即容易出现转移，并且影响预后。研究表明，lncRNA与甲状腺癌的转移有密切关系。申请者前期通过高通量测序，发现lncRNA CTD-3193O13.11在甲状腺癌原发灶及转移灶中表达显著增高。该lncRNA与甲状腺癌的关系，国内外尚未见报道；空间结构分析提示该lncRNA能够和miRNA141结合；组织样本检测发现miRNA141的靶蛋白Evi5L呈现协同高表达。据此我们提出科学假说：该lncRNA可能通过内源性竞争结合miRNA141上调Evi5L的表达，进而激活其下游MAPK、Shh、Wnt等重要信号通路，促进甲状腺癌上皮间质转化和侵袭转移。本项目将通过细胞实验、动物移植瘤模型，研究lncRNA CTD-3193O13.11调控miRNA141/Evi5L的具体分子机制及其对甲状腺癌侵袭转移的影响，为甲状腺癌的综合治疗提供新的策略和靶点。

Thyroid cancer is prone to metastasize at the early stage, which leads to a poor prognosis. Present studies have found that lncRNAs play an important role in thyroid cancer metastasis. Previously, we have found a new lncRNA CTD-3193O13.11 is significantly up-regulated both in the primary and the metastatic tissues of thyroid cancer by using high-throughput sequencing. The relationship between CTD-3193O13.11 and thyroid cancer has not been reported at present. Spatial structural analysis suggested that CTD-3193O13.11 has effective binding sites to miRNA141. Simultaneously, Evi5L which is the target protein of miRNA141 showed synergistic high expression with CTD-3193O13.11 in thyroid cancer tissue. Based on these studies, we hypothesized that the new lncRNA CTD-3193O13.11 may up-regulate the expression of Evi5L by endogenous competive binding to miRNA141, thus leading to the activation of important downstream signaling pathways such as MAPK, Shh, Wnt and promoting the epithelial-mesenchymal-translation and metastasis of thyroid cancer. This project, through the use of molecular biotechnology in cancer cell lines and xenograft animal, plans to further explore the precise biological process about CTD-3193O13.11 regulates thyroid cancer metastasis by targeting miRNA141/EVi5L. Thus providing new strategies and therapeutic targets for the comprehensive treatment of thyroid cancer.